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Diffusion tensor imaging (DTI) is a sensitive tool for detecting brain tissue microstructural
alterations in Parkinson’s disease (PD). Abnormal cerebral perfusion patterns have also
been reported in PD patients using arterial spin labeling (ASL) MRI. In this study we
aimed to perform a combined DTI and ASL assessment in PD patients within the
basal ganglia, in order to test the relationship between microstructural and perfusion
alterations. Fifty-two subjects participated in this study. Specifically, 26 PD patients
[mean age (SD) = 66.7 (8.9) years, 21 males, median (IQR) Modified Hoehn and
Yahr = 1.5 (1–1.6)] and twenty-six healthy controls [HC, mean age (SD) = 65.2 (7.5), 15
males] were scanned with 1.5T MRI. Fractional anisotropy (FA), mean diffusivity (MD),
axial diffusivity (AD), radial diffusivity (RD) maps were derived from diffusion-weighted
images, while cerebral blood flow (CBF) maps were computed from ASL data. After
registration to Montreal Neurological Institute standard space, FA, MD, AD, RD and
CBF median values were extracted within specific regions of interest: substantia nigra,
caudate, putamen, globus pallidus, thalamus, red nucleus and subthalamic nucleus.
DTI measures and CBF were compared between the two groups. The relationship
between diffusion parameters and CBF was tested with Spearman’s correlations. False
discovery rate (FDR)-corrected p-values lower than 0.05 were considered significant,
while uncorrected p-values <0.05 were considered a trend. No significant FA, MD and
RD differences were observed. AD was significantly increased in PD patients compared
with HC in the putamen (p = 0.005, pFDR = 0.035). No significant CBF differences
were found between PD patients and HC. Diffusion parameters were not significantly
correlated with CBF in the HC group, while a significant correlation emerged for PD
patients in the caudate nucleus, for all DTI measures (with FA: r = 0.543, pFDR = 0.028;
with MD: r = −0.661, pFDR = 0.002; with AD: r = −0.628, pFDR = 0.007; with RD:
r = −0.635, pFDR = 0.003). This study showed that DTI is a more sensitive technique
than ASL to detect alterations in the basal ganglia in the early phase of PD. Our results
suggest that, although DTI and ASL convey different information, a relationship between
microstructural integrity and perfusion changes in the caudate may be present.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disease that is characterized by early dopaminergic neuron loss
in the substantia nigra pars compacta, leading to dopamine
deficiency in the basal ganglia, and resulting in movement
disorders (Kalia and Lang, 2015). Although non-motor
symptoms such as sleep disorders, depression and cognitive
impairment may be present, resting tremor, bradykinesia and
rigidity are the hallmarks of the disease (Kalia and Lang, 2015;
Obeso et al., 2017).
Parkinson’s disease diagnosis still remains largely clinical,
based on the three cardinal symptoms onset, (Postuma et al.,
2015) while dopamine transporter (DaT) single photon emission
computerized tomography is currently used to confirm the
clinical diagnosis (Seifert and Wiener, 2013). Nevertheless,
the search for biomarkers with magnetic resonance imaging
(MRI) is an area of active research in the field of PD.
A number of MRI-based methods have been proposed to
provide sensitive and non-invasive quantitative biomarkers of
neurodegeneration (Obeso et al., 2017). In this framework,
diffusion tensor imaging (DTI) and arterial spin labeling (ASL)
are advanced MRI techniques that specifically allow for tissue
integrity assessment (Alexander et al., 2007) and cerebral blood
flow (CBF) quantification, respectively (van Osch et al., 2018).
Parameters derived from DTI, such as fractional anisotropy
(FA) and mean diffusivity (MD), are suitable for investigating
microstructural changes in the brain. MD provides a measure
of overall diffusivity, while FA quantifies the extent to which
diffusion is characterized by a preferential orientation. In
addition to FA and MD, axial diffusivity (AD) and radial
diffusivity (RD) can also be computed from DTI data. AD
represents the primary eigenvalue describing water diffusivity
while RD is determined by the average of the two smaller
eigenvalues. Alterations of FA, MD, AD, and RD in white matter
(WM), cortical and subcortical gray matter (GM) have been
previously reported in PD patients, mirroring neurodegeneration
and possible brain reorganization due to the disease (Atkinson-
Clement et al., 2017). Furthermore, DTI measures in the
subcortical areas were shown to be sensitive makers of disease
progression in PD, (Cochrane and Ebmeier, 2013; Scherfler et al.,
2013; Wei et al., 2016; Atkinson-Clement et al., 2017) even
at the early stages of the disease (Taylor et al., 2018). DTI
changes in the substantia nigra of PD patients were observed
to be associated with increasing dopaminergic deficits, reduced
α-synuclein and total tau protein concentrations in cerebrospinal
fluid, while diffusivity alterations in the thalamus were correlated
with cognitive decline in PD (Zhang et al., 2016).
Together with neuronal degeneration, metabolic and
perfusion parameters may also be altered in PD due to
either neurovascular unit function changes or increased
cerebrovascular disease burden associated with aging (Al-
Bachari et al., 2014). Given the value of CBF as a biomarker in
PD, ASL MRI is a promising technique for PD assessment since
it allows absolute CBF assessment without using an exogenous
contrast agent (Pyatigorskaya et al., 2014). Indeed, abnormal
cerebral perfusion patterns in PD have been revealed using
ASL (Melzer et al., 2011). In addition, this technique proved to
be effective in detecting CBF alterations in non-demented PD
patients (Syrimi et al., 2017) and arterial transit time changes in
idiopathic PD (Al-Bachari et al., 2014).
The combined assessment of FA and CBF has recently been
proposed as an effective method for investigating pathological
changes in the early stages of PD (Wei et al., 2016). Decreased
FA in the substantia nigra and reduced CBF in the basal ganglia
were reported in the same group of patients, hinting that different
neuro-pathological processes may underlie the degeneration
in the subcortical regions primarily involved in the disease
(Wei et al., 2016).
To the best of our knowledge, MD, AD, and RD have not been
assessed together with CBF as of yet. Furthermore, a correlation
analysis between DTI and ASL-derived parameters is still missing
in PD. Therefore, in this study we aimed to perform a combined
DTI and ASL assessment in early PD patients to investigate FA,
MD, AD, RD, and CBF alterations in the basal ganglia regions
with respect to healthy controls (HC). In addition, we aimed to
evaluate the correlation between microstructural and perfusion
parameters. Due to the neurovascular coupling, a potential link
between them was expected.
MATERIALS AND METHODS
Subjects
Fifty-two subjects (26 PD patients and 26 HC) were included
in this study. PD patients were consecutively recruited from
the Neurorehabilitation Unit of the IRCCS Fondazione Don
Gnocchi in Milan, while HC were enrolled between hospital
personnel and volunteers. Only probable PD patients diagnosed
according to the Movement Disorder Society Clinical Diagnostic
Criteria for PD (Postuma et al., 2015) and with positive DaT
scan were included in the study. Other inclusion criteria for PD
group were: mild to moderate stages of the disease (Modified
Hoehn and Yahr − H&Y<3), (Postuma et al., 2015) stable
drug therapy with either L-Dopa or dopamine agonists, freezing
assessed with Movement Disorder Society-sponsored revision
of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
part II lower than 2, time spent with dyskinesias assessed with
MDS-UPDRS part IV lower than 2. Left-handed subjects, people
with history of psychiatric disorders, neurological diseases other
than PD, cardiovascular and/or metabolic diseases were excluded
from the study. All the enrolled PD patients were clinically
evaluated by an experienced neurologist within 2 weeks of the
MRI scan. Specifically, the H&Y Scale and the MDS-UPDRS
were used to assess the severity of PD symptoms (Goetz
et al., 2004). Levodopa equivalent daily dose (LEDD) was
also calculated for each PD patient (Tomlinson et al., 2010).
Montreal Cognitive Assessment (MoCA) was used to evaluate
the cognitive status of all recruited subjects to exclude frank
dementia. For PD patients, additional cognitive assessments
included the Trail Making Test (TMT), phonemic fluency and
semantic fluency.
The study was approved by the IRCCS Fondazione Don Carlo
Gnocchi Ethics Committee and performed in accordance with
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the principles of the Helsinki Declaration. Written and informed
consent was obtained from all the participants.
MRI Acquisition
All the enrolled subjects were scanned on a 1.5T Siemens
Magnetom Avanto scanner, equipped with a 12-channel head
coil. The MRI protocol included:
– Structural sequences:
– A dual-echo turbo spin echo proton density
PD/T2-weighted image [repetition time (TR) = 5550 ms,
echo time (TE) = 23/103 ms, matrix size = 320 × 320 × 45,
resolution 0.8 × 0.8 × 3 mm3] to exclude the presence of
WM hyperintensities beyond those expected as a part of
normal aging;
– A 3D high-resolution T1-weighted image obtained with
a magnetization-prepared rapid acquisition with gradient
echo (MPRAGE) sequence (TR = 1900 ms, TE = 3.37 ms,
TI = 1100 ms, matrix size = 192 × 256 × 176, resolution
1 × 1 × 1 mm3) as anatomical reference, and to evaluate
GM volume differences between groups;
– A 2D T1-weighted anatomical image with 5 mm-thick axial
slices (TR/TE = 393/12 ms, matrix size = 128 × 128 × 26,
resolution = 1.7× 1.7× 5 mm3) as anatomical reference for
CBF map registration;
– Diffusion-weighted echo planar images (EPI) along 64
directions (b-value = 1500 s/mm2) and 3 b0 images (2 with
A-P, 1 with P-A phase encoding) with the same parameters
(TR/TE = 7800/109 ms, matrix size = 102 × 102 × 46,
resolution = 2.5× 2.5× 2.5 mm3);
– Multi-delay pseudo-continuous ASL (pCASL) sequence with
background suppressed 3D gradient and spin echo (GRASE)
readout (TR/TE = 3500/22.58 ms, labeling duration = 1500 ms,
5 post-labeling delays (PLD) = [700, 1200, 1700, 2200, 2700]
ms, 12 pairs of tag/control images for each delay, matrix
size = 64 × 64 × 32, resolution = 3.5 × 3.5 × 5 mm3,
distance between the center of imaging slices and labeling
plane of 90 mm; 3 M0 images acquired with TR = 5000 ms)
(Wang et al., 2013).
MRI Processing
A visual quality check was performed for all the acquired
MRI data prior to any analysis. MRI data processing was
performed with FMRIB’s Software Library (FSL1) unless
otherwise specified.
To avoid voxel misclassification during GM, WM
and cerebrospinal fluid (CSF) automated segmentation,
age-associated WM hyperintensities were identified (if any) on
PD/T2-weighted images by an experienced neuroradiologist.
Hyperintensities were segmented with Jim software, version
6.02, and the obtained masks were registered to corresponding
MPRAGE images with Advanced Normalization Tools (ANTs3)
1http://www.fmrib.ox.ac.uk/fsl
2http://www.xinapse.com/
3http://stnava.github.io/ANTs
in order to perform lesion filling. Non-brain tissue was
removed from lesion-filled MPRAGE image, then brain tissue
classification was performed with SIENAX (Smith et al., 2002).
For processing of the diffusion-weighted images, the
susceptibility-induced off-resonance field was estimated with
the topup tool (Andersson et al., 2003). The eddy tool was then
used to simultaneously correct images for eddy currents and
subject movement as well as susceptibility-induced geometric
distortions (Andersson and Sotiropoulos, 2016). Diffusion
tensor estimation for each voxel was performed with dtifit
(Behrens et al., 2003) and FA maps were derived. Each FA
map was registered to the Montreal Neurological Institute
(MNI) FA template with non-linear transformation, and the
tensor was warped accordingly. Then, MD, AD, and RD
maps were derived.
ASL raw data were corrected for movement with ANTs,
then tag images were subtracted from control ones. CBF
maps were calculated with the oxford_asl tool (Chappell et al.,
2009) (tissue T1 = 1.2 s, T1 of blood = 1.36 s, tagging
efficiency = 0.8) (Wang et al., 2013; Laganà et al., 2018) and
calibrated with the asl_calib tool (Chappell et al., 2009) by
adjusting for CSF magnetization extracted from M0 images.
Partial volume effect (PVE) correction was performed based
on the assumption that CBF in the GM is 2.5 times greater
than in the WM (Marshall et al., 2016). Finally, GM CBF
maps were registered to MNI standard space. To do this,
PVE-corrected CBF maps were first linearly registered to the
respective 2D T1-weighted images, characterized by the same
slice thickness of ASL data, using ANTs. Then, non-linear
registration to MNI standard space was performed via the
MPRAGE with ANTs.
For each subject, median values of CBF, FA, MD, AD,
and RD were extracted within specific regions of interest
(ROIs). Specifically, median CBF, FA, MD, AD, and RD
values were computed across the voxels in each ROI, namely
caudate, putamen, globus pallidus, thalamus, substantia nigra,
red nucleus and subthalamic nucleus. The Harvard-Oxford atlas
was used to generate caudate, putamen, globus pallidus, and
thalamus masks. Substantia nigra, red nucleus and subthalamic
nuclei were defined from the Multi-contrast PD25 atlas (Xiao
et al., 2015) and registered to MNI standard space. All the
ROIs were eroded with a gaussian kernel (sigma = 2 mm)
before performing the extraction of the median values of the
parameters of interest.
To check for potential GM volume differences between
PD patients and HC within the basal ganglia, voxel-based
morphometry (VBM) was performed. This analysis was used to
exclude that potential differences in diffusion parameters could
be due to GM atrophy. Specifically, each subject’s GM map
was non-linearly registered to MNI standard space, modulated
with the Jacobian of the warp field and smoothed with a
Gaussian kernel (sigma = 3 mm). GM volume voxel-wise
comparison between the two groups was performed with the
randomize tool, (Winkler et al., 2014) correcting for age and
sex (ANCOVA), and using threshold-free cluster enhancement
for cluster detection with 5000 permutations. The analysis
was restricted to the basal ganglia regions of interest (i.e.,
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substantia nigra, caudate, globus pallidus, putamen, thalamus,
red nucleus and subthalamic nucleus). VBM results were family
wise error (FWE) corrected at p < 0.05 to account for
multiple comparisons.
Statistical Analysis
Normality of data distributions was tested with the Shapiro-Wilk
test and parametric or non-parametric statistics were
used accordingly.
Age and sex differences between PD and HC group were
tested with an independent samples t-test and Chi-squared
test, as appropriate.
Since L-Dopa or dopamine agonists may have an impact on
CBF, (Chen et al., 2015; Lin et al., 2016) LEDD and CBF were
non-parametrically correlated (Spearman’s) with one another for
all ROIs. In case of significant bivariate correlation, LEDD was
included as a covariate.
The Mann-Whitney U-test was used to compare FA, MD,
AD, RD and CBF measures between PD patients and HC.
The relationship between each diffusion parameter and CBF
was tested with Spearman’s correlations, in PD and HC group
separately. The Benjamini-Hochberg procedure was performed
to control for the false discovery rate (FDR). FDR-corrected
p-values lower that 0.05 were considered significant. Uncorrected
p-values lower than 0.05 were considered as trends. Eta squared
was computed to estimate the effect size and subsequently
transformed to Cohen’s d values. Effect size was classified as very
small for d< 0.2, small for 0.2≤ d<0.5, moderate for 0.5≤ d<0.8
and large for d ≥ 0.8.
Additional analyses to assess the relationship between
diffusion and perfusion alterations and disease duration were
performed and are described in Supplementary Material (see
Supplementary Table 1). In addition, correlation analysis
between FA, MD, AD, RD, and CBF and the neuropsychological
test scores were performed and are shown in Supplementary
Material (see Supplementary Table 2).
RESULTS
Demographics
PD and HC groups were age- and sex-matched (p = 0.527
and p = 0.071, respectively). PD patients and HC had a
mean (standard deviation-SD) age of 66.7 (8.9) and 65.2
(7.5) years old, respectively. The PD group was characterized
by a median (interquartile range-IQR) H&Y of 1.5 (1–1.6),
and by a mean (SD) MDS-UPDRS III of 19.2 (11.2). The
median adjusted MoCA (Santangelo et al., 2015) of the
PD group and HC group was 24.3 and 25.6, respectively.
Demographic and clinical characteristics of the two groups are
reported in Table 1.
MRI Parameters Group Comparison
All the MRI images were classified as good quality scans and
included in the analysis.
No significant correlation was found between CBF and LEDD
in any ROI (results not shown). For this reason, LEDD was not
considered as covariate in the following analysis.
TABLE 1 | Demographic and clinical characteristics of the participants of the study.
HC (n = 26) PD (n = 26) p-value
Males, n (%) 15 (57.7) 21 (80.8) 0.071a
Age in yrs, mean (SD) 65.2 (7.5) 66.7 (8.9) 0.527b
H&Y, median (IQR) na 1.5 (1− 1.6) –
MDS-UPDRS III score during on periods, mean (SD) na 19.2 (11.2) –
Disease duration in yrs, median (IQR) – 3 (2− 4) –
Onset laterality, left n (%) – 10 (38.5) –
Antiparkinsonian medications
Levodopa-containing drugs, n (%) – 11 (42.3) –
Dopamine agonists, n (%) 11 (42.3)
MAO-B inhibitors, n (%) 17 (65.4)
LEDD, mean (SD) – 214.2 (121.5) –
Education level in yrs, median (IQR) 16 (13-18) 13 (8− 17.3) 0.060c
MoCA, median (IQR) 25.6 (24.2-27.7) 24.3 (21.6− 26.3) 0.042c
TMT, Part A, median (IQR) na 41.5 (30.3− 63.5) –
TMT, Part B, median (IQR) na 73.5 (58.3− 110.5) –
TMT, B-A, median (IQR) na 40.0 (25.0− 63.8) –
Phonemic fluency, mean (SD) na 32.7 (9.6) –
Semantic fluency, mean (SD) na 39.7 (10.4) –
HC, healthy controls; IQR, interquartile range; LEDD, Levodopa daily dose equivalent; MAO-B, monoamine oxidase-B; Movement Disorder Society-sponsored revision of
the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), MoCA, Montreal Cognitive Assessment, n, number, na, not available, PD, Parkinson’s disease, SD, standard
deviation, TMT, Trail Making Test, yrs, years. MoCA scores were adjusted according to Santangelo et al. (2015), TMT according to Giovagnoli et al. (1996), phonemic
fluency according to Carlesimo et al. (1996) and semantic fluency according to Novelli et al. (1986). Chi-squared test (a), independent samples Student’s t-test (b), and
Mann-Whitney test (c) were used to evaluate differences between PD and HC groups, as appropriate. P-values lower than 0.05 were considered significant (in bold).
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No significant FA differences were observed. MD was
significantly higher in PD patients with respect to HC in the
substantia nigra (p = 0.030, d = 0.631), putamen (p = 0.012,
d = 0.742) and red nucleus (p = 0.036, d = 0.607) but none
of the results survived FDR correction. AD was found to be
significantly higher in PD compared to HC in the putamen
(p = 0.005, d = 0.836), even when correcting for multiple
comparisons (pFDR = 0.035). Increased RD was observed in PD
for the putamen (p = 0.039, d = 0.596) and red nucleus (p = 0.034,
d = 0.616), while higher CBF was found in the subthalamic
nucleus (p = 0.022, d = 0.669) although significance was lost after
FDR correction. Median FA, MD, AD, RD, and CBF values, and
their IQR are reported in Table 2.
The VBM analysis did not show any significant GM volume
differences between PD and HC groups within the basal
ganglia regions.
Correlations Between DTI Parameters
and CBF
No significant correlation was found between any of the diffusion
parameters and CBF in HC group (Supplementary Table 3).
TABLE 2 | Median (IQR) values of FA, MD, AD, RD, and CBF for HC and PD groups within the ROIs.
Parameter ROI HC (n = 26) PD (n = 26) PD vs. HC
p pFDR d
FA Substantia Nigra 0.436 (0.411–0.463) 0.443 (0.422–0.457) 0.570 0.884 0.158
Caudate 0.122 (0.114–0.136) 0.120 (0.109–0.141) 0.714 0.884 0.102
Pallidum 0.241 (0.229–0.247) 0.237 (0.225–0.247) 0.884 0.884 0.041
Putamen 0.140 (0.131–0.149) 0.139 (0.131–0.147) 0.840 0.884 0.056
Thalamus 0.260 (0.250–0.271) 0.253 (0.244–0.261) 0.055 0.385 0.553
Red Nucleus 0.372 (0.333–0.392) 0.355 (0.326–0.374) 0.305 0.712 0.287
Subthalamic nucleus 0.437 (0.422–0.461) 0.434 (0.406–0.449) 0.257 0.712 0.319
MD Substantia Nigra 0.725 (0.698–0.759) 0.750 (0.731–0.775) 0.030 0.084 0.631
[10−3 mm2/sec] Caudate 0.726 (0.706–0.850) 0.766 (0.715–1.004) 0.227 0.281 0.340
Pallidum 0.736 (0.707–0.759) 0.743 (0.717–0.780) 0.464 0.464 0.204
Putamen 0.685 (0.675–0.704) 0.704 (0.694–0.718) 0.012 0.084 0.742
Thalamus 0.733 (0.725–0.763) 0.754 (0.739–0.770) 0.073 0.128 0.514
Red nucleus 0.620 (0.595–0.647) 0.646 (0.621–0.658) 0.036 0.084 0.607
Subthalamic nucleus 0.666 (0.651–0.690) 0.677 (0.660–0.701) 0.241 0.281 0.329
AD Substantia Nigra 1.117 (1.064–1.172) 1.147 (1.088–1.195) 0.188 0.373 0.372
[10−3 mm2/sec] Caudate 0.836 (0.810–0.957) 0.874 (0.831–1.105) 0.162 0.373 0.396
Pallidum 0.919 (0.891–0.977) 0.921 (0.890–0.994) 0.721 0.721 0.099
Putamen 0.783 (0.769–0.802) 0.807 (0.792–0.825) 0.005 0.035 0.836
Thalamus 0.947 (0.935–0.996) 0.968 (0.949–0.995) 0.213 0.373 0.350
Red Nucleus 0.868 (0.830–0.914) 0.807 (0.792–0.825) 0.375 0.525 0.248
Subthalamic Nucleus 0.995 (0.973–1.022) 0.987 (0.951–1.021) 0.674 0.721 0.117
RD Substantia Nigra 0.543 (0.498–0.563) 0.559 (0.538–0.579) 0.082 0.134 0.497
[10−3 mm2/sec] Caudate 0.682 (0.656–0.801) 0.719 (0.662–0.957) 0.241 0.281 0.329
Pallidum 0.650 (0.623–0.670) 0.663 (0.631–0.691) 0.365 0.365 0.253
Putamen 0.637 (0.627–0.655) 0.653 (0.635–0.667) 0.039 0.124 0.596
Thalamus 0.633 (0.625–0.660) 0.657 (0.639–0.674) 0.053 0.124 0.556
Red nucleus 0.481 (0.470–0.527) 0.519 (0.500–0.530) 0.034 0.124 0.616
Subthalamic nucleus 0.507 (0.488–0.537) 0.529 (0.495–0.547) 0.096 0.134 0.475
CBF Substantia Nigra 26.86 (22.98–30.80) 24.86 (20.58–31.60) 0.634 0.840 0.132
[ml/min/100 g] Caudate 21.63 (18.21–24.41) 20.75 (16.72–24.07) 0.608 0.840 0.142
Pallidum 19.99 (18.21–24.43) 21.83 (19.65–24.84) 0.241 0.840 0.329
Putamen 25.14 (21.54–29.18) 24.02 (21.50–28.47) 0.840 0.840 0.056
Thalamus 25.92 (19.59–30.45) 23.44 (21.29–27.97) 0.687 0.840 0.112
Red Nucleus 27.94 (23.39–33.87) 27.58 (23.47–32.28) 0.728 0.840 0.097
Subthalamic Nucleus 22.65 (20.83–27.23) 28.56 (23.20–31.07) 0.022 0.154 0.669
AD, axial diffusivity; CBF, cerebral blood flow; FA, fractional anisotropy; d, Cohen’s d; FDR, false discovery rate; HC, healthy controls; IQR, interquartile range; MD, mean
diffusivity; n, number; PD, Parkinson’s disease; RD, radial diffusivity; ROI, region of interest. The group differences were tested with Mann-Whitney test. Original p-values,
FDR-corrected p-values and Cohen’s d are reported. P-values lower than 0.05 were considered significant (in bold). Effect sizes were originally calculated as eta squared
and subsequently transformed into Cohen’s d values. Effect size was considered very small for d < 0.2, small for 0.2 ≤ d < 0.5, moderate for 0.5 ≤ d < 0.8, and large
for d ≥ 0.8. Note that obtained p-values lower than 0.05 are associated with moderate to large effect size.
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Conversely, for the PD group, significant FDR-corrected
correlations were found between CBF and all the diffusion
parameters in the caudate nucleus (with FA: r = 0.543,
pFDR = 0.028; with MD: r = −0.661, pFDR = 0.002; with AD:
r =−0.628, pFDR = 0.007; with RD: r =−0.635, pFDR = 0.003; see
Table 3). The scatterplots representing diffusion-vs.-perfusion
measures in the caudate in the PD group are reported in Figure 1.
DISCUSSION
In the current study a combined assessment of DTI parameters
and CBF within the basal ganglia was performed in a group of
idiopathic PD patients to investigate the relationship between
microstructural integrity and perfusion alterations. Three main
findings were obtained. First, microstructural alteration was
shown in the putamen, a region that is primarily involved
in PD. In addition, no significant perfusion differences were
observed between PD and HC in any of the considered ROIs.
Finally, a significant correlation between DTI parameters and
CBF emerged for PD patients in the caudate.
The presence of DTI alterations in PD has been extensively
discussed over the last decade but without drawing final
conclusions, as conflicting results have been reported (Cochrane
and Ebmeier, 2013; Schwarz et al., 2013; Atkinson-Clement et al.,
2017). Since the loss of dopaminergic neurons leads to the
disruption of diffusion barriers, decreased FA and increased MD,
TABLE 3 | Spearman’s correlation between local CBF and diffusion parameters in PD group (n = 26) within all the ROIs.
ROI FA MD AD RD
r pFDR r pFDR r pFDR r pFDR
Substantia Nigra +0.058 0.777 +0.015 0.941 −0.016 0.939 +0.201 0.692
Caudate +0.543 0.028 −0.661 0.002 −0.628 0.007 −0.635 0.003
Pallidum +0.382 0.126 −0.112 0.682 −0.032 0.939 −0.110 0.692
Putamen −0.096 0.747 +0.320 0.391 +0.345 0.294 +0.0211 0.692
Thalamus +0.128 0.747 −0.156 0.666 −0.175 0.688 −0.164 0.692
Red nucleus −0.431 0.098 −0.236 0.572 −0.275 0.406 +0.024 0.906
Subthalamic Nucleus +0.239 0.420 −0.284 0.666 −0.201 0.706 +0.123 0.692
AD, axial diffusivity; CBF, cerebral blood flow; FA, fractional anisotropy; FDR, false discovery rate; MD, mean diffusivity; PD, Parkinson’s disease; RD, radial diffusivity; ROI,
region of interest. P-values lower than 0.05 were considered significant (in bold).
FIGURE 1 | Scatterplots showing FA, MD, AD, and RD in the caudate in relation to CBF in the PD group (panel A–D, respectively). Spearman’s correlation
coefficients and associated FDR-corrected p-values are shown (significant for pFDR < 0.05). CBF, cerebral blood flow; FA, fractional anisotropy; FDR, false discovery
rate; HC, healthy control; MD, mean diffusivity; AD, axial diffusivity; PD, Parkinson’s disease; r-Spearman’s correlation coefficient; RD, radial diffusivity.
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AD and RD are expected in PD (Atkinson-Clement et al., 2017;
Winklewski et al., 2018). Nevertheless, some recent studies also
showed increased FA and decreased diffusivities in PD (Lenfeldt
et al., 2015; Mole et al., 2016; Wen et al., 2016; Chen et al.,
2018) In addition, varied multifocal patterns of abnormal DTI
changes were reported, (Karagulle Kendi et al., 2008; Zhan et al.,
2012) probably due to the multisystem involvement and the
non-motor syndromes that characterize the disease (Hall et al.,
2016). In the present study, significantly increased AD and a
trend for higher MD and RD were found for PD patients in the
putamen. The putamen is a key region for motor symptoms in
PD, (Manza et al., 2016) since it is densely connected with the
motor cortex. Therefore, its structural alterations are strongly
associated with PD motor deficits (Nemmi et al., 2015) which
are the cardinal symptoms of the disease. Notably, our PD group
showed a trend for altered diffusivity also in the substantia nigra.
Specifically, a trend for increased MD was observed, in line
with several previous studies that reported altered nigral MD
in PD (Scherfler et al., 2013; Schwarz et al., 2013; Du et al.,
2014; Kamagata et al., 2016; Loane et al., 2016). Furthermore,
a significant correlation between RD in the substantia nigra
and TMT, part A score (Supplementary Table 2) was found.
Conversely, no significant FA alterations were detected within the
substantia nigra of PD patients in this study. Although this result
is in contrast with several previous studies that reported reduced
FA in PD, (Yoshikawa et al., 2004; Chan et al., 2007; Vaillancourt
et al., 2009; Wei et al., 2016) heterogeneous FA alterations have
been reported, so that FA in the substantia nigra has been
considered insufficiently sensitive and specific to diagnose PD
(Schuff et al., 2015; Hirata et al., 2017). The relatively limited
sample size probably prevented us from consistently showing
significant alterations of all the DTI parameters in the putamen
and in the substantia nigra of our PD patients. However, the
significantly altered AD in the putamen and the observed trends,
associated with moderate to large effect sizes, suggest that DTI
changes are present in the putamen and in the substantia nigra
in early PD. The absence of group differences in terms of GM
volumes within the regions showing DTI alterations highlighted
that the loss of micro-structural integrity was without gross tissue
loss (i.e., atrophy). Thus, the deafferentation of the nigrostriatal
pathway likely induces a complex microstructural reorganization
in the putamen and substantia nigra (Peran et al., 2010).
Besides DTI measures, ASL-derived CBF values were also
tested in this study. No significant CBF differences between
PD patients and HC were found within any of the ROIs.
However, a trend for increased perfusion (significant before
FDR-correction) was observed within the subthalamic nucleus.
Hypermetabolism of the subthalamic nucleus, reflected by
greater CBF, is in concordance with increased neuronal activity
and an irregular firing pattern, as previously reported in PD
(Hutchison et al., 1998; Blandini et al., 2000; Rodriguez-Oroz
et al., 2001). The important role of the subthalamic nucleus in
PD symptomatology and in direct-indirect pathway imbalance
is supported by the dramatic clinical benefits experienced by
PD patients after neurosurgery (both ablation and deep brain
stimulation) targeting this structure (Obeso et al., 2017). Unlike
in the DTI analysis, we did not detect any differences in
putaminal perfusion in our PD patients. Our result of preserved
CBF in the putamen is in line with some previous studies
(Melzer et al., 2011; Al-Bachari et al., 2014; Pelizzari et al.,
2019) but in contrast with a recent one that showed putaminal
hypoperfusion in PD patients, both at early and middle stage
of the disease (Wei et al., 2016). The considerable clinical
heterogeneity that characterizes PD could have prevented us
from identifying common patterns of CBF alterations in the
basal ganglia in early PD patients. Investigating CBF in a wider
cohort of PD patients at the early stage and accounting for
motor symptom laterality onset is warranted to clarify the role
of CBF changes in PD.
Interestingly, strongly significant correlations between all
the DTI parameters and CBF were observed in the caudate
nucleus of our PD patients, even though neither diffusion
nor perfusion indices were altered. The caudate nucleus is
known to be relatively spared at the early stage of the disease.
A slower rate of dopaminergic decline in the caudate nucleus
with respect to the putamen was reported by a previous study,
with no significant changes in the caudate during the first
years of the disease (Bruck et al., 2009). The dorsal caudate
nucleus is connected with the dorsolateral prefrontal cortex,
and it is part of the cognitive loop, which was proposed to
be affected immediately after the motor one in PD (de la
Fuente-Fernandez, 2012). Therefore, the absence of diffusion
and perfusion changes in the caudate might be associated with
the early disease stage. However, a correlation between DTI
parameters and CBF was observed in this study. Specifically,
PD patients who presented microstructural alterations in the
caudate, showed also hypoperfusion. Both microstructural
damage and perfusion alterations might be associated with
disease duration (Supplementary Table 1), thus longitudinal
studies are warranted to confirm their potential link with
disease progression.
This study is not without limitations. The sample size
was relatively small and the results remain to be confirmed
in a larger number of patients. In addition, the relatively
low resolution of ASL MRI, together with the small size
of the ROIs, may have prevented us from showing the
expected perfusion alterations. Another limitation that has
to be mentioned is that the study was performed with a
1.5T MRI scanner. Although 3T scanners are characterized
by a higher signal-to-noise ratio, the investigation of
non-invasive markers to evaluate PD patients even with
lower-field scanners, which are still prevalent in the clinical
practice, is important in a translational perspective for
diagnosis, treatment efficacy assessment and in terms of
PD monitoring. The lack of a fine-grained neuropsychological
assessment and the heterogeneity of our PD group in terms of
laterality onset have also to be mentioned as limitations. This
probably prevented us from showing consistent correlations
between neuropsychological scores and MRI parameters
(Supplementary Table 2). Finally, although we expected to
find an association between perfusion changes and alterations
of diffusion indices, only longitudinal studies may confirm the
association with disease progression and allow for more firm
conclusions to be drawn.
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CONCLUSION
In conclusion, DTI appears to be a more sensitive technique
than ASL to detect changes in basal ganglia regions of early PD
patients when using 1.5T clinical scanners. However, since CBF
in the caudate correlates with respective DTI parameters, both
microstructural alterations and hypoperfusion may potentially be
involved in caudate neurodegeneration and in the development
of further symptoms in later stages of the disease.
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